Alector (ALEC) Research & Development (2018 - 2026)
Alector (ALEC) posted quarterly Research & Development of $17.9 million for Q1 2026, down 46.92% year-over-year from $33.6 million in Q1 2025, and down 44.99% quarter-over-quarter from $32.5 million in Q4 2025.
Alector (ALEC) Research & Development (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported Research & Development for 9 consecutive years, with $17.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 46.92% year-over-year to $17.9 million; the TTM figure through Mar 2026 stood at $107.3 million (down 38.49% YoY), while the FY2025 annual figure was $123.1 million, down 33.81% from the prior year.
- Research & Development eased to $17.9 million in Q1 2026 per ALEC's latest filing, from $32.5 million in the prior quarter.
- Across five years, Research & Development topped out at $54.5 million in Q2 2022 and bottomed at $17.9 million in Q1 2026.
- Historically, Research & Development has averaged $42.9 million across 5 years, with a median of $46.3 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development increased 15.98% — and 2026, when it tumbled 46.92%.
- Alector's Research & Development stood at $54.5 million in 2022, then fell by 12.42% to $47.7 million in 2023, then slipped by 2.64% to $46.5 million in 2024, then tumbled by 30.13% to $32.5 million in 2025, then plunged by 44.99% to $17.9 million in 2026.
- Business Quant data shows ALEC's Research & Development at $17.9 million in Q1 2026, $32.5 million in Q4 2025, and $29.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Alector | 218.85 Mn | 46.05 Mn | - | 19.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.46 Mn |
| Mar 31, 2026 | 17.86 Mn |
| Dec 31, 2025 | 32.46 Mn |
| Sep 30, 2025 | 29.35 Mn |
| Jun 30, 2025 | 27.61 Mn |
| Mar 31, 2025 | 33.64 Mn |
| Dec 31, 2024 | 46.46 Mn |
| Sep 30, 2024 | 48.00 Mn |
| Jun 30, 2024 | 46.31 Mn |
| Mar 31, 2024 | 45.17 Mn |
| Dec 31, 2023 | 47.72 Mn |
| Sep 30, 2023 | 46.33 Mn |
| Jun 30, 2023 | 46.18 Mn |
| Mar 31, 2023 | 51.89 Mn |
| Dec 31, 2022 | 54.49 Mn |
| Sep 30, 2022 | 48.35 Mn |
| Jun 30, 2022 | 54.53 Mn |
| Mar 31, 2022 | 53.04 Mn |
| Dec 31, 2021 | 52.79 Mn |
| Sep 30, 2021 | 43.07 Mn |